UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): October 9, 2014
|
BioCorRx Inc. |
|
(Exact name of registrant as specified in its charter) |
333-153381
(Commission File Number)
|
Nevada |
26-0685980 |
|
|
(State or other jurisdiction |
(I.R.S. Employer |
|
|
of Incorporation) |
Identification No.) |
601 N. Parkcenter Drive, Suite 103
Santa Ana, California 92705
(Address of principal executive offices)
(714) 462-4880
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Item 7.01 Regulation FD Disclosure.
On October 9, 2014, BioCorRx, Inc., a Nevada corporation (the “Company”), issued a press release announcing a shareholder conference call to be held on October, 16, 2014 at 11:00am Pacific Time, to discuss its financial results through June 30, 2014 and its operational outlook for the remainder of 2014 and 2015.
The information furnished pursuant to Item 7.01 (including Exhibit 99.1 hereto), shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Exhibits
The following exhibits are furnished as part of this Form 8-K:
|
Exhibit 99.1 |
Press Release, dated October 9, 2014, issued by BioCorRx, Inc. |
|
2
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOCORRX INC. |
|||
| Date: October 9, 2014 | By: |
/s/ Lourdes Felix |
|
|
Lourdes Felix Chief Financial Officer and Director |
|||
3